Loading patent…
AssigneeEnzymotec Ltd.
InventorsDaphna Zaaroor Regev, Robert Chudnow, Yael Richter, Olga Gali Soria Artzi
Estimating the term…
The preparation of the present invention was found to be effective for the majority of patients diagnosed with autism. In patients characterized by delayed language development and non-expressive/non-emotional communication patterns, the preparation of the invention was found to be more effective than in patients that were diagnosed with autism without delayed language development and with expressive/emotional communication patterns, even though all patients consumed the preparation for a similar duration. Specific analysis for the type and quality of the improvement detected within the group of patients characterized by delayed language development and non-expressive/non-emotional communication patterns revealed that the majority of patients improved in various communication abilities: speech, language, conversation, and social play.
A preparation comprising:
The preparation of any one of the preceding claims, wherein the percentage by weight of PS with respect to the total phospholipids in the preparation is greater than 30%.
The preparation of any of the preceding claims, wherein the percentage of EPA attached to the PS in the preparation with respect to the total fatty acid content attached to the PS in the preparation is greater than 18% and lower than 45%.
The preparation of any one of the preceding claims, wherein the percentage of Palmitic acid attached to the PS in the preparation with respect to the total fatty acids content attached to the PS in the preparation is greater than 14% and lower than 42%.
The preparation of any one of the preceding claims, wherein the percentage of DHA attached to the PS in the preparation with respect to the total fatty acids content attached to the PS in the preparation is greater than 6% and lower than 25%.
The preparation of any one of the preceding claims, wherein the percentage of Oleic acid attached to the PS in the preparation with respect to the total fatty acids content attached to the PS in the preparation is greater than 1% and lower than 15%.
The preparation of any one of the preceding claims, wherein the percentage of Linoleic acid attached to the PS in the preparation with respect to the total fatty acids content attached to the PS in the preparation is greater than 0.1% and lower than 6.0%.
The preparation of any one of the preceding claims, further comprising a phosphatidylcholine (PC).
The preparation of any one of the preceding claims, wherein a ratio by weight of the PS to the sum of phosphatidic acid and the lysophosphatidic acid in the preparation is greater than 1:1 and lower than 10:1.
A composition comprising the preparation of any one of the above claims wherein the composition is a nutritional composition, nutraceutical, functional food, or medicinal food.
A pharmaceutical composition comprising the preparation of any one of the above claims.
A method for improving communication comprising administering a therapeutically effective amount of the preparation or composition of any of the preceding claims to a subject.
Dependencies are inferred from the claim text.